Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RPTX 
Repare Therapeutics Inc (RPTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: RPTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.23% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 75.61M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 4 | Beta 0.93 | 52 Weeks Range 0.89 - 4.07 | Updated Date 09/15/2025 |
52 Weeks Range 0.89 - 4.07 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8024.8% |
Management Effectiveness
Return on Assets (TTM) -38.82% | Return on Equity (TTM) -69.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -33214858 | Price to Sales(TTM) 302.43 |
Enterprise Value -33214858 | Price to Sales(TTM) 302.43 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA 0.58 | Shares Outstanding 42959200 | Shares Floating 22715092 |
Shares Outstanding 42959200 | Shares Floating 22715092 | ||
Percent Insiders 1.25 | Percent Institutions 64.93 |
Upturn AI SWOT
Repare Therapeutics Inc
Company Overview
History and Background
Repare Therapeutics Inc. was founded in 2016. It is a clinical-stage precision oncology company focused on discovering, developing and commercializing novel therapeutics targeting specific DNA damage repair (DDR) pathways.
Core Business Areas
- Oncology Therapeutics: Development of precision oncology therapeutics that target DNA damage repair (DDR) pathways in cancer cells.
Leadership and Structure
Repare is led by President and CEO, Lloyd Segal. The company has a typical corporate structure with departments focused on research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Camonsertib (RP-3500): Camonsertib is a potent and selective oral inhibitor of ATR (ataxia telangiectasia and Rad3-related protein) kinase, being developed for advanced solid tumors with ATR pathway dependencies. Clinical trials are underway. Competitors include companies developing other ATR inhibitors, such as Vertex Pharmaceuticals (VXRT) and Merck KGaA.
- RP-6306: RP-6306 is an oral, selective PKMYT1 inhibitor currently in phase I clinical trials for advanced solid tumors with CCNE1 amplification. Competitors include other companies developing PKMYT1 inhibitors.
Market Dynamics
Industry Overview
The oncology therapeutics market is a large and growing market, driven by the increasing incidence of cancer and the development of new and more effective treatments. Precision oncology, which targets specific genetic mutations or biomarkers, is a rapidly growing segment of the market.
Positioning
Repare is positioned as a precision oncology company focused on DDR pathways. Its competitive advantage lies in its proprietary discovery platform, SNIPRxu00ae, which identifies novel targets for DDR inhibition. It is also based on the clinical advancement of its drugs.
Total Addressable Market (TAM)
The total addressable market for DDR inhibitors is estimated to be multi-billion dollars and growing. Repare is positioned to capture a significant share of this market with its pipeline of novel DDR inhibitors. The TAM is based on the number of patients with tumors having DDR pathway dependencies, which is a significant percentage of cancer patients.
Upturn SWOT Analysis
Strengths
- Proprietary SNIPRxu00ae discovery platform
- Strong pipeline of novel DDR inhibitors
- Experienced management team
- Strategic partnerships with larger pharmaceutical companies
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Reliance on clinical trial success
- Susceptible to competition from larger pharmaceutical companies
Opportunities
- Expansion of pipeline through SNIPRxu00ae platform
- Potential for strategic partnerships and collaborations
- Positive clinical trial results
- Increasing adoption of precision oncology
Threats
- Clinical trial failures
- Competition from other DDR inhibitors
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- VXRT
- MRK
Competitive Landscape
Repare competes with both large pharmaceutical companies and smaller biotech companies in the precision oncology space. Its advantage lies in its SNIPRxu00ae platform, but it faces challenges from larger companies with more resources.
Growth Trajectory and Initiatives
Historical Growth: As a clinical-stage company, historical growth is primarily defined by pipeline progression and securing funding.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst projections vary.
Recent Initiatives: Recent initiatives include advancing camonsertib and RP-6306 through clinical trials and expanding the pipeline through the SNIPRxu00ae platform.
Summary
Repare Therapeutics is a clinical-stage precision oncology company with a promising pipeline of DDR inhibitors. Its proprietary SNIPRxu00ae platform provides a competitive advantage. However, the company faces significant risks associated with clinical trial success and competition. Future success hinges on positive clinical data and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Repare Therapeutics Inc. website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary. Financial data is based on information from publicly available sources and has not been independently verified.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repare Therapeutics Inc
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2020-06-19 | President, CFO, CEO & Director Mr. Steve Forte CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 129 | Website https://www.reparerx.com |
Full time employees 129 | Website https://www.reparerx.com | ||
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.